ABCA7 transporter functional role on Alzheimer’s disease onset and progess

Identification of new drug targets and biomarkers with a true clinical potential to treat or at least modify the disease course of Alzheimer’s disease (AD) has become a major challenge. Despite newly identified, GWAS-derived risk factors for AD, this type of genetic information only represents the surface layer of a deep multidimensional network impacting ND pathogenesis. GWAS studies have recently highlight ABCA7 transporter as a risk marker for AD. We will assess existing and newly generated large-scale targeted proteomics data from animal cohorts to unravel the interplay and interactions of metabolites, lipids and proteins contributing to ABCA7-related disease pathogenesis. We want to understand the complex and multi-factorial mechanisms taking place at the metabolism level – including regulatory and signaling aspects – that contribute to AD onset and progression. By doing so, we will enable the identification of more drugable targets that are linked to this risk factor activity and open up novel starting points for pharmacological interventions and possibly prevention. Our work will also allow for a better disease understanding and the identification of novel metabolic biomarkers, which may help in disease monitoring and patient stratification for clinical